Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 12/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25356682 | 0.82 | PDPK1 (0.49) | GSK3B | |
| SCHEMBL27751008 | 0.78 | MPO (0.41) | MAP2K4MAPK1MAPK6ITKHTR2A | |
| SCHEMBL23908909 | 0.78 | CYP1A2 (0.53) | MAP2K4 | |
| SCHEMBL30727481 | 0.78 | CYP1A2 (0.53) | MAP2K4 | |
| SCHEMBL5953156 | 0.78 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6MAP2K7ITK | |
| SCHEMBL23914767 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKGSK3B | |
| SCHEMBL31010860 | 0.73 | MAP2K4 (0.50) | MAP2K4MAPK1MAPK6MAP2K7DAO | |
| SCHEMBL14979221 | 0.73 | MAP2K4 (0.54) | MAP2K4MAPK1MAPK6MAP2K7ITK | |
| SCHEMBL7713988 | 0.72 | MAP2K4 (0.49) | MAP2K4MAPK1MAPK6MAP2K7ITK | |
| SCHEMBL5677771 | 0.71 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6MAP2K7ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAP2K4 4247/4885MAPK1 1776/4885MAPK6 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.